(Q37405555)

English

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

scientific article published on 02 February 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

Sunanda Kane

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

William Holderman

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Peter Jacques

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Todd Miodek

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

2 February 2008

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Patient Preference and Adherence

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

253-258

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

6 September 2017

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

6 September 2017

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

6 September 2017

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

26 June 2018

Colorectal cancer prevention in ulcerative colitis: a case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

26 June 2018

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

26 June 2018

Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

26 June 2018

Predictors of medication adherence in inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

2 September 2018

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

2 September 2018

Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

2 September 2018

Cigarette smoking and ulcerative colitis: a case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770408

2 September 2018

Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A general method of compliance assessment using centralized pharmacy records. Description and validation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of smoking on the presentation and clinical course of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19920971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/PPA.S3698

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37405555&oldid=1704743772"